Evidence map›Paper›PMID 40244868›Full record

ArticleThoracic cancer2025

Baseline and changes in inflammatory parameters for patients with EGFR-mutated NSCLC treated with afatinib.

Zi-Ting Chang, Ping-Chih Hsu, How-Wen Ko, John Wen-Cheng Chang, Chen-Te Wu, Chen-Yang Huang, Ching-Fu Chang, Chih-Hsi Scott Kuo, Cheng-Ta Yang, Chiao-En Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zi-Ting ChangDepartment of Internal Medicine, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Ping-Chih HsuDivision of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.
How-Wen KoDivision of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.
John Wen-Cheng ChangDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Chen-Te WuDepartment of Medical Imaging and Intervention, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Chen-Yang HuangDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Ching-Fu ChangDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Chih-Hsi Scott KuoDivision of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Cheng-Ta YangDivision of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Chiao-En WuDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.ORCID https://orcid.org/0000-0002-1900-2984

Funding

Chang Gung Memorial Hospital, Linkou CMRPG3K2Chang Gung Memorial Hospital, Linkou CMRPG3L0912Chang Gung Memorial Hospital, Linkou CMRPG3M0521Chang Gung Memorial Hospital, Linkou CMRPG3M0971National Science and Technology Council 109-2314-B-182-080-MY3National Science and Technology Council 111-2811-B-182-017
6 · The paper itself

Abstract

backgroundThis study investigated the relationship between inflammatory biomarkers (lymphocyte ratio [NLR], monocyte-to-lymphocyte ratio [MLR], and platelet-to-lymphocyte ratio [PLR]) and the treatment outcomes of patients with non-small cell lung cancer (NSCLC) treated with afatinib.

methodsThe patients with NSCLC treated with afatinib between June 2014 and February 2018 were retrospectively reviewed. Their inflammatory biomarkers and clinical outcomes (progression-free survival [PFS] and tumor response) were explored using univariate and multivariate analyses.

resultsAmong 325 patients, those with an NLR >2.18, MLR >0.19, and PLR >177.73 had significantly worse PFS than those with lower values. After adjusting for performance status, stage, and liver metastasis, the PFS was still unfavorable for a baseline NLR >2.18, MLR >0.19, or PLR > 177.73. Among 188 patients with paired inflammatory values, those whose NLR decreased by >29.5%, MLR decreased by >57.9%, and PLR increased by <18.8% had significantly better PFS. After adjusting for performance status, stage, and liver metastasis, the PFS was significantly unfavorable for an NLR decrease of <29.5% and MLR decrease of <57.9%. Among the patients with tumor response, NLR, MLR, and PLR significantly decreased after treatment (all p < 0.05).

conclusionsOur study presented the NLR, MLR, and PLR as prognostic factors for patients with NSCLC treated with afatinib. Further investigation into these markers representing the tumor microenvironment and their association with cancer status is crucial for evaluating prognosis and clinical outcomes in patients with NSCLC.

Indexed as

AfatinibCarcinoma, Non-Small-Cell LungInflammationLung NeoplasmsMutationAdultAgedAged, 80 and overErbB ReceptorsFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesAfatinibEGFR protein, humanErbB Receptorsmonocyte‐to‐lymphocyte rationeutrophil‐to‐lymphocyte ratioplatelet‐to‐lymphocyte ratioprognostic factorstreatment outcomes

Identifiers

PMID40244868
PMCPMC12238321

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.